Skip to main content
Premium Trial:

Request an Annual Quote

BioBase Signs Celera, Exelixis, Clontech for Access to Transfac Database

NEW YORK, April 18 – Celera, Clontech Laboratories, and Exelixis have subscribed to BioBase’s Transfac Professional database of transcription factors and regulation, the company said Wednesday.

Under the terms of the agreement, Cognia, the North American distributor of Transfac Professional, will provide it along with Match, a new tool that allows users to locate transcription factor binding sites in sequences.

The companies did not disclose the financial terms of the agreements.

“Transfac Professional may help these researchers accelerate their discovery processes by helping them understand and navigate more efficiently through their research data,” said Holger Karas, CEO of BioBase.  

Transfac Professional is a relational database system of transcription information from plant, yeast, mouse, and human factors. BioBase, of Braunschweig, Germany has also added SNP information from the SNP consortium. BioBase continues to curate this database.

Other customers for Transfac include Eli Lilly, Schering-Plough Research Institute, Aventis Pharma, and the Akzo Nobel-subsidiary Organon.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.